7. Goodwill, Indefinite-Lived Intangible Assets and Other Long-Term Assets (Details Narrative) - USD ($) |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2020 |
Dec. 31, 2019 |
Oct. 31, 2019 |
|
Indefinite-lived Intangible Assets [Line Items] | |||
Asset impairment charge | $ 9,243,128 | $ 3,283,379 | |
Other Assets | 809,985 | 1,213,042 | |
Prepaid expenses and other | 200,000 | 700,000 | |
Serum Institute of India Ltd [Member] | |||
Indefinite-lived Intangible Assets [Line Items] | |||
Prepaid clinical supply | 700,000 | 700,000 | |
Pharmsynthez Loan [Member] | |||
Indefinite-lived Intangible Assets [Line Items] | |||
Note receivable face amount | $ 500,000 | ||
Note receivable interest rate | 10.00% | ||
Interest income | 51,000 | $ 9,000 | |
Pharmsynthez Loan Extension [Member] | |||
Indefinite-lived Intangible Assets [Line Items] | |||
Periodic payment | $ 25,000 | ||
Frequency of payment | Monthly | ||
Other Assets | $ 100,000 | ||
Prepaid expenses and other | $ 500,000 |
X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Description of the frequency of periodic payments (monthly, quarterly, annual). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of the required periodic payments including both interest and principal payments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Amount of interest and fee income from loans classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of noncurrent assets classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets. No definition available.
|
X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Note receivable face amount No definition available.
|
X | ||||||||||
- Definition Note receivable interest rate No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|